Research

Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4

Abdel-Rahman N Zekri¹ , Hanaa M Alam El-Din¹ , Abeer A Bahnassy² , Naglaa A Zayed³ , Waleed S Mohamed¹ , Suzan H El-Masry⁴ , Sayed K Gouda⁴ and Gamal Esmat³

¹  Virology and Immunology Unit, Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt

²  Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt

³  Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt

⁴  Biochemistry Department, Faculty of Science, Cairo University, Giza, Egypt

author email corresponding author email

Comparative Hepatology 2010, 9:1doi:10.1186/1476-5926-9-1

Published:	5 January 2010

Abstract

Background

Liver disease progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) is associated with an imbalance between T-helper 1 and T-helper 2 cytokines. Evaluation of cytokines as possible candidate biomarkers for prediction of HCC was performed using soluble Fas (sFas), soluble tumor necrosis factor receptor-II (sTNFR-II), interleukin-2 receptor (IL-2R) and interleukin-8 (IL-8).

Results

The following patients were recruited: 79 with HCV infection, 30 with HCC, 32 with chronic liver disease associated with elevated liver enzyme levels (with or without cirrhosis) in addition to 17 with chronic HCV with persistent normal alanine aminotransferase levels (PNALT). Nine normal persons negative either for HCV or for hepatitis B virus were included as a control group. All persons were tested for sFas, sTNFR-II, IL-2R and IL-8 in their serum by quantitative ELISA. HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups. HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups. Exclusion of HCC among patients having PNALT could be predicted with 90% sensitivity and 70.6% specificity when sTNFR-II is ≥ 389 pg/ml or IL-8 is < 290 pg/ml.

Conclusions

Serum TNFR-II, IL-2Rα and IL-8, may be used as combined markers in HCV-infected cases for patients at high risk of developing HCC; further studies, however, are mandatory to check these findings before their application at the population level.